IMMUNITYBIO, INC. Increase (Decrease) in Accounts Receivable
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Accounts Receivable of $10.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-04
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $10.20M, a 100.14% increase year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $700.00K, a 95.23% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $10.55M.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $9.89M, a 214.77% increase year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for fiscal 2025 was $40.21M, a 1603.86% increase from fiscal 2024.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for fiscal 2024 was $2.36M.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
- IMMUNITYBIO, INC. increase (decrease) in accounts receivable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $10.90M 10-Q · filed 2026-08-04 | $21.46M derived: sum of 3 quarters · filed 2026-08-04 | $31.35M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-07 | $11.26M derived: sum of 2 quarters · filed 2026-05-07 | $21.14M derived: sum of 3 quarters · filed 2026-05-07 | $26.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $10.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $20.45M derived: sum of 2 quarters · filed 2026-02-23 | $25.54M derived: sum of 3 quarters · filed 2026-08-04 | $40.21M 10-K · filed 2026-02-23 |
| 2025-09-30 | $9.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $14.99M derived: sum of 2 quarters · filed 2026-08-04 | $29.66M 10-Q · filed 2025-11-05 | $27.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $19.77M 10-Q · filed 2026-08-04 | $17.95M derived: sum of 3 quarters · filed 2026-08-04 | $21.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $14.67M 10-Q · filed 2026-05-07 | $12.85M derived: sum of 2 quarters · filed 2026-05-07 | $16.00M derived: sum of 3 quarters · filed 2026-05-07 | $17.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.33M derived: sum of 2 quarters · filed 2026-02-23 | $2.36M derived: sum of 3 quarters · filed 2026-02-23 | $2.36M 10-K · filed 2026-02-23 |
| 2024-09-30 | $3.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.17M derived: sum of 2 quarters · filed 2025-11-05 | $4.17M 10-Q · filed 2025-11-05 | $4.17M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.03M 10-Q · filed 2025-08-05 | $1.03M derived: sum of 3 quarters · filed 2026-02-23 | $1.03M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |||
| 2016-06-30 | $3.00K 10-Q · filed 2016-08-15 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $25.00K derived: sum of 2 quarters · filed 2016-03-30 | $30.00K derived: sum of 3 quarters · filed 2016-08-15 | -$75.00K 10-K · filed 2016-03-30 |
| 2015-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $30.00K derived: sum of 2 quarters · filed 2016-08-15 | -$75.00K 10-Q · filed 2015-11-12 | -$19.00K derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$100.00K 10-Q · filed 2016-08-15 | -$44.00K derived: sum of 3 quarters · filed 2016-08-15 | -$5.00K derived: sum of 4 quarters · filed 2016-08-15 |
| 2015-03-31 | -$105.00K 10-Q · filed 2016-05-16 | -$49.00K derived: sum of 2 quarters · filed 2016-05-16 | -$10.00K derived: sum of 3 quarters · filed 2016-05-16 | |
| 2014-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $95.00K derived: sum of 2 quarters · filed 2016-03-30 | -$95.00K 10-K · filed 2016-03-30 | |
| 2014-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$151.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$190.00K 10-Q · filed 2015-09-10 | |||
| 2013-12-31 | $173.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |